Chaemsaithong P, Sahota D, Pooh RK, et al. - Researchers examined whether the European‐derived biomarker multiples of the median (MoM) formulae is applicable for risk assessment of preterm preeclampsia (PE) in seven Asian populations, spanning the east, southeast and south regions of the continent. In addition, they performed quality‐assurance (QA) assessment of the biomarker measurements and established criteria for prospective ongoing QA assessment of biomarker measurements. In 11 recruiting centers in China, Hong Kong, India, Japan, Singapore, Taiwan and Thailand, they conducted a prospective, non‐intervention, multicenter study in 4,023 singleton pregnancies, at 11 to 13 + 6 weeks' gestation. Observations revealed significant differences in biomarker MoM values for PE screening, particularly MAP and PlGF MoMs, in Asian populations compared with the expected values based on European‐derived formulae; this is due to the anthropometric differences in Asian compared with Caucasian women. Among women in all centers, QA assessment tools revealed consistently lower MAP MoM values than expected, but these values were within 10% of the expected value. At all sites except one, UtA‐PI MoM values were within 10% of the expected value. They mostly noted systematically 10% lower PlGF MoM values than the expected value, except for those derived from a South Asian population, which were 37% higher. For reporting reliable and consistent patient‐specific risks for preterm PE, they suggest performing adjustment for additional factors or necessity for development of Asian‐specific formulae for the calculation of biomarker MoMs. Further, they demonstrated the significance and necessity for regular quality assessment of biomarker values.